Drug Profile
LX 2761
Alternative Names: LX-2761Latest Information Update: 20 Jul 2023
Price :
$50
*
At a glance
- Originator Lexicon Pharmaceuticals
- Class Amides; Antihyperglycaemics; Benzhydryl compounds; Small molecules; Thioglycosides
- Mechanism of Action Sodium-glucose transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 20 Jul 2023 LX 2761 is still in phase-I trials for Type-2-diabetes-mellitus in USA (PO) (Lexicon Pharmaceuticals pipeline, July 2023)
- 28 Feb 2023 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO)
- 02 Feb 2021 LX 2761 is still in phase I trial in Type 2 diabetes mellitus in USA (Lexicon Pharmaceuticals pipeline, February 2021)